Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2008 | Editorial

Vaccination and screening programs: harmonizing prevention strategies for HPV-related diseases

Authors: Luciano Mariani, Sonia Pagliusi

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2008

Abstract

HPV vaccine is an exciting promise of the preventive medicine. Although HPV-immunization programs still reveal a number of unanswered questions, they represent a novel opportunity for primary prevention against cervical cancer and other HPV-related pre-neoplastic and neoplastic diseases. It is reasonable that the short and long-term benefits of vaccination on cervical and vulvo-vaginal HPV-related pathology will emerge when assuring over time a clear and complete information to the community and harmonizing the prevention strategies. Indeed, HPV-vaccination programs will require an understanding of new paradigms of infection and cancer control, and thus will require a rationale integration with the currently operating screening systems.

zur Hausen H, de Villiers EM, Gissmann L: Papillomavirus infections and human genital cancer. Gynecol Oncol. 1981, 12: S124-8. 10.1016/0090-8258(81)90067-6.CrossRef

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.CrossRef

Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002, 55 (4): 244-65.CrossRef

Frazer I: HPV immunisation: A significant advance in cancer control. Gynecol Oncol. 2007, 107: S1-10.1016/j.ygyno.2007.07.071.CrossRef

Lippman A, Melnychuk R, Shimmin C, Boscoe M: Human papillomavirus, vaccines and women's health: questions and cautions. CMAJ. 2007, 177 (5): 484-487.CrossRef

Gostin LO, DeAngelis CD: Mandatory HPV Vaccination. Public Health vs Private Wealth. JAMA. 2007, 297 (17): 1921-1923. 10.1001/jama.297.17.1921.CrossRef

Bosch FX, Castellsague X', de Sanjose' S: HPV and cervical cancer: screening or vaccination?. British Journal of Cancer. 2008, 98: 15-21. 10.1038/sj.bjc.6604146.CrossRef

Stanley M: Human Papillomavirus Vaccines versus Cervical Cancer Screening. Clin Oncol (R Coll Radiol). 2008, 20 (6): 388-94.CrossRef

Rambout L, Hopkins L, Hutton B, Fergusson D: Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ. 2007, 177 (5): 469-79.CrossRef

10.

Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003, 88 (1): 63-73. 10.1038/sj.bjc.6600688.CrossRef

11.

Munoz N, Bosch FX, Castellsague X, Dýaz M, de Sanjose S, Hammouda D, Shah KV: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004, 111 (2): 278-85. 10.1002/ijc.20244.CrossRef

12.

Preuss SF, Klussmann JP, Jungehulsing M, Eckel HE, Guntinas-Lichius O, Damm M: Long-term results of surgical treatment for recurrent respiratory papillomatosis. Acta Otolaryngol. 2007, 127 (11): 1196-201. 10.1080/00016480701200350. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518–27CrossRef

13.

Gerein V, Schmandt S, Babkina N, Barysik N, Coerdt W, Pfister H: Human papillomavirus (HPV)-associated gynecological alteration in mothers of children with recurrent respiratory papillomatosis during long-term observation. Cancer Detect Prev. 2007, 31 (4): 276-81. 10.1016/j.cdp.2007.07.004. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006, 24(Suppl 3):S26–34CrossRef

14.

Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348: 518-27. 10.1056/NEJMoa021641.CrossRef

15.

Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006, 24 (Suppl 3): S26-34. 10.1016/j.vaccine.2006.05.026.CrossRef

16.

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, Disease (FUTURE) I Investigators: Quadrivalent Vaccine against Human. Papillomavirus to Prevent Anogenital Diseases. N Engl J Med. 2007, 356: 1928-43. 10.1056/NEJMoa061760.CrossRef

17.

FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007, 356: 1915-27. 10.1056/NEJMoa061741.CrossRef

18.

The Future II Study Group: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007, 369: 1861-68. 10.1016/S0140-6736(07)60852-6.CrossRef

19.

Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, G for the HPV PATRICIA study group: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007, 369: 2161-70. 10.1016/S0140-6736(07)60946-5.CrossRef

20.

Hildesheim A, Herrero R, Wacholder S, Rodriguez A, Solomon D, Bratti C, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR, for the Costa Rican HPV Vaccine Trial Group: Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection A Randomized Trial. JAMA. 2007, 298 (7): 743-753. 10.1001/jama.298.7.743.CrossRef

21.

Dunne EF, Karem KL, Sternberg MR, Stone R, Unger E, Reeves WC, Markowitz LE: Seroprevalence of Human Papillomavirus type 16 in children. Journal of Infectious Disease. 2005, 191: 1817-1819. 10.1086/430274.CrossRef

22.

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, for the Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP): Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm. 2007, Rep 56: 1-24.

23.

Department of health and human services centers for disease control and prevention: Advisory Committee on Immunization Practices. Summary report. February 27–28, 2008, [http://www.cdc.gov/vaccines/recs/acip/downloads/min-feb08.pdf]

24.

Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B: Psychosocial aspects of vaccine acceptability. Vaccine. 2006, 24 (S3): 201-9. 10.1016/j.vaccine.2006.06.017.CrossRef

25.

Garland S, Park S, Ngan HYS, Frazer I, Tay EH, Chen CJ, Bhatla N, Pitts M, Shin HR, Konno6 R, Smith J, Pagliusi S, Park JS: The need for public education on HPV and cervical cancer prevention in Asia. Opinions of experts at the AOGIN Conference. Vaccine. 2008

26.

Franco EL, Cuzick J: Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine. 2008, 26 (Suppl 1): A16-23. 10.1016/j.vaccine.2007.11.069.CrossRef

27.

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N: New Technologies for Cervical Cancer Screening Working Group: Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008, 100 (7): 492-501. 10.1093/jnci/djn065.CrossRef

28.

Nieminen P, Anttila A: Introducing HPV screening: challenges and fallacies. Acta Obstet Gynecol Scand. 2007, 86 (12): 1416-8. 10.1080/00016340701698757.CrossRef

29.

Wentzensen N, von Knebel Doeberitz M: Biomarkers in cervical cancer screening. Dis Markers. 2007, 23 (4): 315-30.CrossRef

30.

Elbasha EH, Dasbach EJ, Insinga RP: Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007, 13 (1): 28-41.CrossRef

31.

Goldie S: A public health approach to cervical cancer control: considerations of screening and vaccination strategies. Int J Gynecol Obst. 2006, 94 (Suppl 1): 95-105. 10.1016/S0020-7292(07)60016-2.CrossRef

32.

Kulasingam SL, Pagliusi P, Myers E: Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. Vaccine. 2007, 25: 8110-8113. 10.1016/j.vaccine.2007.09.035.CrossRef

33.

Insinga R, Dasbach E, Allen S, Carides C, Myers E: Reductions in Human Papillomavirus-Disease Resource Use and Costs with Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination: The FUTURE Study Economic Evaluation. Value Health. 2008, 16: 1-11.

34.

Pagliusi S, Lawson H, Singer A, Monsonego J: EUROGIN 2007 Patient Education Conference: Sharing experiences and action in cervical cancer prevention – an overview2007. Vaccine. 2008, 26S: A33-A36. 10.1016/j.vaccine.2007.11.075.CrossRef

Title: Vaccination and screening programs: harmonizing prevention strategies for HPV-related diseases
Authors: Luciano Mariani
Sonia Pagliusi
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2008
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-27-84

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma

Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160

Follicular dendritic cell sarcoma of the neck: Report of a case treated by surgical excision and COP plus (PEG)-liposomal doxorubicin

How should tracers be injected to detect for sentinel nodes in gastric cancer – submucosally from inside or subserosally from outside of the stomach?

The cytosol activity of thymidine phosphorylase in endometrial cancer

Sp1 is involved in H2O2-induced PUMA gene expression and apoptosis in colorectal cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer